drugset / Trial / NCT00320203

Anecortave Acetate in Patients With Open-angle Glaucoma

NCT00320203

Phase 2 Completed 86 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, efficacy, and duration of effect of a single administration of Anecortave Acetate Depot for treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma.

Timeline

Start
2006-03
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule 3 mg Other
Subject Anecortave Acetate Small molecule 15 mg Other
Subject Anecortave Acetate Small molecule 30 mg Other

Indications